Ultime notizie per Evergy (NASDAQ:EVRG) Azioni

Evergy

Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission Co. The utility has a combined rate base of approximately $20 billion, about half in Kansas and the rest split between Missouri and federal jurisdiction. Evergy is one of the largest wind energy suppliers in the US.

Capital One Savor Cash Rewards Credit Card

Personal Finance

CADE

EVRG

Flussi di cassa costanti e in crescita: la ricetta per un investimento vincente? Tre titoli che premiano gli azionisti con generosità.

Reddito passivo? Ecco 3 aziende che aumentano i dividendi da anni

Macro Economic Events

News

Global

Economics

Reuters Cites Saudi Energy Ministry Saying It Confirms Saudi Arabia Has Remained Fully Compliant With Its Voluntary OPEC+ Target

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) with a Market Perform and lowers the price target from $13 to $12.

Price Target

Analyst Ratings

NEWT

Keefe, Bruyette & Woods Maintains Market Perform on NewtekOne, Lowers Price Target to $12

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains Middlefield Banc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBCN#NASDAQ">MBCN</a>) with a Market Perform and raises the price target from $30 to $32.

MBCN

Keefe, Bruyette & Woods Maintains Market Perform on Middlefield Banc, Raises Price Target to $32

<a href="https://x.com/Alibaba_Qwen/status/1943692825566355819" title="https://x.com/Alibaba_Qwen/status/1943692825566355819">https://x.com/Alibaba_Qwen/status/1943692825566355819</a>

BABA

'Alibaba launches Qwen Chat for desktop. The new Qwen. ai platform offers three tools in one: Qwen Chat for brainstorming and creating, a Research section to keep up with Qwen's latest work, and the Qwen API to build your own AI-powered apps. The desktop version now supports MCP for smarter, faster agents and better productivity.'

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains Live Oak Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOB#NYSE">LOB</a>) with a Market Perform and raises the price target from $34 to $36.

Keefe, Bruyette & Woods Maintains Market Perform on Live Oak Bancshares, Raises Price Target to $36

Scotiabank analyst Kevin Fisk maintains Parex Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PXT#TSX">PXT</a>) with a Sector Perform and raises the price target from C$14 to C$16.

TSX:PXT

Scotiabank Maintains Sector Perform on Parex Resources, Raises Price Target to C$16

Keefe, Bruyette &amp; Woods analyst Catherine Mealor downgrades Hancock Whitney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWC#NASDAQ">HWC</a>) from Outperform to Market Perform and raises the price target from $62 to $63.

Downgrades

Keefe, Bruyette & Woods Downgrades Hancock Whitney to Market Perform, Raises Price Target to $63

Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) has outperformed the market over the past 15 years by 26.02% on an annualized basis producing an average annual return of 38.47%. Currently, Morningstar has a market capitalization of $12.79 billion. 
Buying $100 In MORN: If an investor had bought $100 of MORN stock 15 years ago, it would be worth $13,244.82 today based on a price of $299.00 for MORN at the time of writing.
<h3>Morningstar's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752248718_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

MORN

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains Green Dot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) with a Market Perform and raises the price target from $11 to $12.

GDOT

Keefe, Bruyette & Woods Maintains Market Perform on Green Dot, Raises Price Target to $12

Keefe, Bruyette &amp; Woods analyst Catherine Mealor upgrades FB Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) from Market Perform to Outperform and raises the price target from $52 to $58.

Upgrades

Keefe, Bruyette & Woods Upgrades FB Financial to Outperform, Raises Price Target to $58

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Customers Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBI#NYSE">CUBI</a>) with a Market Perform and raises the price target from $65 to $70.

CUBI

Keefe, Bruyette & Woods Maintains Market Perform on Customers Bancorp, Raises Price Target to $70

<a href="https://www.globenewswire.com/Tracker?data=1Hv_JrhYMWM9DUvj8H1p7vRcpU3ZVE9yhcTGdCgHIwHUwzxZhpY4EY0SxKXr7mPtNt6kJI5dlZDyLpxHva8Yse-oDPI6amtesfs4Sp4lr4Q=">Valneva SE</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>, PARIS:<a class="ticker" href="https://www.benzinga.com/stock/VLA#PARIS">VLA</a>), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva's single-dose chikungunya vaccine IXCHIQ&#xAE; by EMA's safety committee (PRAC).
The committee initiated its review at the beginning of May following the occurrence of serious side effects mainly in elderly people with several underlying medical conditions. In a press release published today on its website1, EMA underlined that the vaccine is already contraindicated for people with a weakened immune system and concluded that, for people of all ages, IXCHIQ&#xAE; should be given when there is a significant risk of chikungunya infection and after a careful consideration of the benefits and risks.
Additionally, EMA noted that while most serious side effects occurred in older people, IXCHIQ&#xAE; is effective at triggering the production of antibodies against the chikungunya virus which may be of particular benefit for older people who are at increased risk of severe chikungunya disease.
IXCHIQ&#xAE; was authorised in the European Union in June 20242 and, in March 2025, the European Commission granted a label extension in adolescents 12 years of age and older3.

Biotech

General

PARIS:VLA

VALN

Valneva's Chikungunya Vaccine IXCHIQ Cleared By European Medicines Agency For Use In Seniors After Safety Committee Review

Warren Buffett may still be <a href="https://www.benzinga.com/topic/warren-buffett">calling the shots in Omaha</a>, but the stock market appears to be pricing in a world without him &#8211; and fast.
During the second quarter of 2025, Berkshire Hathaway's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) Class B shares underperformed the S&amp;P 500 Index by a historic margin, lagging the benchmark by nearly 18 percentage points since the May 3rd shareholder meeting, when Buffett reiterated his retirement succession plan. 
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="1006" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11102807/Screenshot-2025-07-11-at-7.57.42-PM.png" alt="" class="wp-image-982001" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11102807/Screenshot-2025-07-11-at-7.57.42-PM.png 1006w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11102807/Screenshot-2025-07-11-at-7.57.42-PM-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11102807/Screenshot-2025-07-11-at-7.57.42-PM-768x437.png 768w" sizes="(max-width: 1006px) 100vw, 1006px" /></figure>
Source: TradingView
What makes this stretch remarkable isn't just the scale of the drop — it's that this is the biggest quarterly underperformance in the history of the stock, outside of the Covid crash (exception being the second quarter of 2020).
Read Also: <a href="https://www.benzinga.com/markets/equities/25/07/46313514/warren-buffetts-quiet-dividend-play-9-high-yield-stocks-held-by-a-berkshire-subsidiary">Warren Buffett&#8217;s Quiet Dividend Play: 9 High-Yield Stocks Held By A Berkshire Subsidiary</a>
<h2 class="wp-block-heading">This Isn't Just Another Rough Patch</h2>
Berkshire has had off quarters before, but rarely one this severe. In the second quarter of 2020, the market was in chaos, reacting violently to pandemic shutdowns, Fed shockwaves, and unprecedented global uncertainty.
In contrast, the second quarter of 2025 has been relatively stable and broadly bullish, with the S&amp;P 500 powering higher on AI euphoria, tech strength, and a resilient consumer.
So what's dragging Berkshire down? Likely, a mix of rotation out of value-heavy sectors, fading interest in financials and industrials, and a psychological shift as investors begin to think more tangibly about the post-Buffett era.
<h2 class="wp-block-heading">From Aura To Arithmetic</h2>
For decades, Berkshire traded with a halo &#8211; the &#8216;Buffett Premium&#8217; &#8211; a valuation lift rooted in investor faith in the Oracle's judgment and capital discipline. That premium now seems to be eroding. 
Without Buffett's active presence or new bold moves to counteract the market's pivot to growth and innovation, Berkshire is beginning to look like just another value stock.
And markets are treating it accordingly.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46109576/buffett-premium-fading-away-the-oracle-of-omahas-retirement-casts-shadow-on-berkshire-hathaways-stock-value-report">&#8216;Buffett Premium&#8217; Fading Away? The Oracle Of Omaha&#8217;s Retirement Casts Shadow On Berkshire Hathaway&#8217;s Stock Value: Report</a></li>
</ul>
Photo: Shutterstock

The Warren Buffett Premium May Finally Be Fading

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains CNB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCNE#NASDAQ">CCNE</a>) with a Market Perform and raises the price target from $25 to $26.

CCNE

Keefe, Bruyette & Woods Maintains Market Perform on CNB Financial, Raises Price Target to $26

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains Coastal Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCB#NASDAQ">CCB</a>) with a Outperform and raises the price target from $110 to $115.

Keefe, Bruyette & Woods Maintains Outperform on Coastal Financial, Raises Price Target to $115

Options

Markets

LWLG

Lightwave Logic Option Alert: Dec 19 $2 Calls At The Ask: 1198 @ $0.25 vs 2940 OI; Earnings 8/8 After Close [est] Ref=$1.3

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains Pathward Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASH#NASDAQ">CASH</a>) with a Market Perform and raises the price target from $86 to $88.

CASH

Keefe, Bruyette & Woods Maintains Market Perform on Pathward Financial, Raises Price Target to $88

WIIM

CENT

CENTA

Central Garden & Pet shares are trading higher after the company announced it raised its FY25 Non-GAAP EPS guidance.

Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) has outperformed the market over the past 5 years by 48.44% on an annualized basis producing an average annual return of 62.77%. Currently, Howmet Aerospace has a market capitalization of $72.07 billion. 
Buying $1000 In HWM: If an investor had bought $1000 of HWM stock 5 years ago, it would be worth $11,769.37 today based on a price of $178.53 for HWM at the time of writing.
<h3>Howmet Aerospace's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752247813_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Axos Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) with a Market Perform and raises the price target from $85 to $90.

Keefe, Bruyette & Woods Maintains Market Perform on Axos Financial, Raises Price Target to $90

Press Releases

Evergy Announces Appointment of Two New Board Members

Evergy Schedules Conference Call to Discuss 3rd Quarter Results

Evergy Announces Two New 705 MW High-Efficiency Natural Gas Plants

Evergy Announces Third Quarter 2024 Results, Increases Quarterly Dividend, Reaffirms 2024 Guidance, Establishes 2025 Guidance

Dye & Durham Releases its Value Creation Plan and Announces its Seven Highly Qualified Nominees for Election at the Upcoming Annual and Special Meeting

Comments

Evergy

Notizie

Ultime notizie per Evergy (NASDAQ:EVRG) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO